Developed during my time as Direction of Animation at AS&K Visual Science, this MOA animation for Bayer Oncology's Xofigo radiopharmaceutical product presented many unique challenges.
The FDA ruling on "fair balance" was quite new - requiring the associated risks to be delivered with a similar weighting as to the benefits - this resulted in over half the runtime being comprised of safety information and disclaimers. Much was interwoven into the animated first half, leaving some ISI and stats to be tagged on at the end. The end result is a reasonably engaging animation that complies with some of the strictest regulatory content controls that I have experienced. Most importantly, the client was happy with the compromise between visual feel and FDA compliance.
Below are a selection of frames from the US specific Xofigo MOA Animation
A branded palette combined with detailed cellular and molecular content was required by the client. The design of the Xofigo molecule, a radiopharmaceutical product for the treatment of cancer, required a delicate approach. Some of the initial design and concept artwork for the Xofigo molecule and its emitted alpha particle, can be viewed below the animation.
To view the final Xofigo MOA Animation, please enter my password below
Initial Artwork and Reference Boards
CONCEPT ARTWORK AND PRODUCTION DESIGN
